OA12167A - Asymmetric synthesis of pregabalin. - Google Patents

Asymmetric synthesis of pregabalin. Download PDF

Info

Publication number: OA12167A
Authority: OA; OAPI
Prior art keywords: cyano; formula; sait; acid; cation
Prior art date: 2000-01-27

Application number

OA1200200227A

Other languages

English (en)

Inventor

Mark Joseph Burk

Om Prakash Goel

Marvin Simon Hoekstra

Thomas Frederick Mich

Thomas Arthur Mulhern

James Andres Ramsden

Original Assignee

Warner Lambert Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-01-27

Filing date

2001-01-11

Publication date

2006-05-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26874236&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA12167(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-01-11 Application filed by Warner Lambert Co filed Critical Warner Lambert Co

2006-05-08 Publication of OA12167A publication Critical patent/OA12167A/en

Links

AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 title claims abstract description 48
229960001233 pregabalin Drugs 0.000 title claims abstract description 36
238000011914 asymmetric synthesis Methods 0.000 title description 3
238000004519 manufacturing process Methods 0.000 claims abstract description 5
238000000034 method Methods 0.000 claims description 48
229910052739 hydrogen Inorganic materials 0.000 claims description 32
239000000203 mixture Substances 0.000 claims description 31
238000006243 chemical reaction Methods 0.000 claims description 25
239000002253 acid Substances 0.000 claims description 24
239000003054 catalyst Substances 0.000 claims description 22
-1 (S)-3-cyano-5-methylhexanoic acid carboxylate Chemical class 0.000 claims description 19
150000001875 compounds Chemical class 0.000 claims description 16
125000000217 alkyl group Chemical group 0.000 claims description 15
MGWZYUMZVZMKTN-ZETCQYMHSA-N (3s)-3-cyano-5-methylhexanoic acid Chemical compound CC(C)C[C@H](C#N)CC(O)=O MGWZYUMZVZMKTN-ZETCQYMHSA-N 0.000 claims description 14
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 14
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 12
150000001768 cations Chemical class 0.000 claims description 12
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
229910052700 potassium Inorganic materials 0.000 claims description 12
239000011591 potassium Substances 0.000 claims description 12
125000004093 cyano group Chemical group *C#N 0.000 claims description 10
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 9
239000003446 ligand Substances 0.000 claims description 8
150000007942 carboxylates Chemical class 0.000 claims description 6
150000001336 alkenes Chemical class 0.000 claims description 5
150000001412 amines Chemical class 0.000 claims description 5
239000003513 alkali Substances 0.000 claims description 4
230000003197 catalytic effect Effects 0.000 claims 2
230000005588 protonation Effects 0.000 claims 2
125000000467 secondary amino group Chemical class [H]N([*:1])[*:2] 0.000 claims 2
125000003277 amino group Chemical group 0.000 claims 1
150000001733 carboxylic acid esters Chemical class 0.000 claims 1
150000003141 primary amines Chemical class 0.000 claims 1
230000015572 biosynthetic process Effects 0.000 abstract description 15
238000003786 synthesis reaction Methods 0.000 abstract description 15
239000000543 intermediate Substances 0.000 abstract description 3
208000028017 Psychotic disease Diseases 0.000 abstract description 2
208000027520 Somatoform disease Diseases 0.000 abstract description 2
206010015037 epilepsy Diseases 0.000 abstract description 2
208000027753 pain disease Diseases 0.000 abstract description 2
150000003839 salts Chemical class 0.000 abstract description 2
238000009876 asymmetric hydrogenation reaction Methods 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 131
239000000243 solution Substances 0.000 description 54
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 41
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 36
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 33
239000001257 hydrogen Substances 0.000 description 31
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 27
239000010948 rhodium Substances 0.000 description 27
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 24
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 24
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 20
239000000047 product Substances 0.000 description 20
239000007787 solid Substances 0.000 description 20
238000003756 stirring Methods 0.000 description 20
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
239000000758 substrate Substances 0.000 description 15
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
239000002002 slurry Substances 0.000 description 13
IFOIXEQWPBMPJK-UHFFFAOYSA-N ethyl 3-cyano-5-methylhex-3-enoate Chemical compound CCOC(=O)CC(C#N)=CC(C)C IFOIXEQWPBMPJK-UHFFFAOYSA-N 0.000 description 12
229960003692 gamma aminobutyric acid Drugs 0.000 description 12
229910052757 nitrogen Inorganic materials 0.000 description 12
235000011118 potassium hydroxide Nutrition 0.000 description 12
AJNZWRKTWQLAJK-KLHDSHLOSA-N (2r,5r)-1-[2-[(2r,5r)-2,5-dimethylphospholan-1-yl]phenyl]-2,5-dimethylphospholane Chemical compound C[C@@H]1CC[C@@H](C)P1C1=CC=CC=C1P1[C@H](C)CC[C@H]1C AJNZWRKTWQLAJK-KLHDSHLOSA-N 0.000 description 11
239000002904 solvent Substances 0.000 description 11
229910052786 argon Inorganic materials 0.000 description 10
239000000463 material Substances 0.000 description 10
239000011541 reaction mixture Substances 0.000 description 10
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
229960000583 acetic acid Drugs 0.000 description 9
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 9
238000004817 gas chromatography Methods 0.000 description 9
PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 9
239000003921 oil Substances 0.000 description 9
229940093932 potassium hydroxide Drugs 0.000 description 9
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 8
150000002148 esters Chemical class 0.000 description 8
125000003118 aryl group Chemical group 0.000 description 7
HZHBIPCFTRPWKY-UHFFFAOYSA-N 3-cyano-5-methylhex-3-enoic acid Chemical compound CC(C)C=C(C#N)CC(O)=O HZHBIPCFTRPWKY-UHFFFAOYSA-N 0.000 description 6
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
206010010904 Convulsion Diseases 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
235000011054 acetic acid Nutrition 0.000 description 6
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 6
238000001953 recrystallisation Methods 0.000 description 6
239000000523 sample Substances 0.000 description 6
YYMLUQVUARAJKK-UHFFFAOYSA-N 3-hydroxy-4-methyl-2-methylidenepentanenitrile Chemical compound CC(C)C(O)C(=C)C#N YYMLUQVUARAJKK-UHFFFAOYSA-N 0.000 description 5
239000012043 crude product Substances 0.000 description 5
239000012065 filter cake Substances 0.000 description 5
239000000706 filtrate Substances 0.000 description 5
239000011521 glass Substances 0.000 description 5
150000002431 hydrogen Chemical class 0.000 description 5
150000002825 nitriles Chemical class 0.000 description 5
238000000746 purification Methods 0.000 description 5
UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 4
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
210000004556 brain Anatomy 0.000 description 4
229910002091 carbon monoxide Inorganic materials 0.000 description 4
230000000694 effects Effects 0.000 description 4
239000010410 layer Substances 0.000 description 4
IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 4
230000008569 process Effects 0.000 description 4
JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 4
239000007858 starting material Substances 0.000 description 4
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
238000005292 vacuum distillation Methods 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
108091022930 Glutamate decarboxylase Proteins 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 3
239000012346 acetyl chloride Substances 0.000 description 3
238000013459 approach Methods 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
239000012467 final product Substances 0.000 description 3
239000012362 glacial acetic acid Substances 0.000 description 3
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
239000002858 neurotransmitter agent Substances 0.000 description 3
229910052759 nickel Inorganic materials 0.000 description 3
239000012044 organic layer Substances 0.000 description 3
230000020477 pH reduction Effects 0.000 description 3
KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
238000010992 reflux Methods 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
239000011734 sodium Substances 0.000 description 3
229910052717 sulfur Inorganic materials 0.000 description 3
239000002699 waste material Substances 0.000 description 3
CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
CDEDUITVVMMHTR-UHFFFAOYSA-N (2-cyano-4-methylpent-1-en-3-yl) ethyl carbonate Chemical compound CCOC(=O)OC(C(C)C)C(=C)C#N CDEDUITVVMMHTR-UHFFFAOYSA-N 0.000 description 2
IWYDHOAUDWTVEP-ZETCQYMHSA-N (S)-mandelic acid Chemical compound OC(=O)[C@@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-ZETCQYMHSA-N 0.000 description 2
CIBMDQOEVWDTDT-ONEGZZNKSA-N (e)-5-methylhex-3-enoic acid Chemical compound CC(C)\C=C\CC(O)=O CIBMDQOEVWDTDT-ONEGZZNKSA-N 0.000 description 2
UWCWUCKPEYNDNV-LBPRGKRZSA-N 2,6-dimethyl-n-[[(2s)-pyrrolidin-2-yl]methyl]aniline Chemical compound CC1=CC=CC(C)=C1NC[C@H]1NCCC1 UWCWUCKPEYNDNV-LBPRGKRZSA-N 0.000 description 2
CYYDDSNDKQYALZ-UHFFFAOYSA-N 2-cyanohexanoic acid Chemical compound CCCCC(C#N)C(O)=O CYYDDSNDKQYALZ-UHFFFAOYSA-N 0.000 description 2
MGWZYUMZVZMKTN-UHFFFAOYSA-N 3-cyano-5-methylhexanoic acid Chemical compound CC(C)CC(C#N)CC(O)=O MGWZYUMZVZMKTN-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
241000206607 Porphyra umbilicalis Species 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000001773 anti-convulsant effect Effects 0.000 description 2
125000003710 aryl alkyl group Chemical group 0.000 description 2
238000003556 assay Methods 0.000 description 2
239000002585 base Substances 0.000 description 2
239000010779 crude oil Substances 0.000 description 2
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
238000004821 distillation Methods 0.000 description 2
238000010931 ester hydrolysis Methods 0.000 description 2
RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000007789 gas Substances 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
XXROGKLTLUQVRX-UHFFFAOYSA-N hydroxymethylethylene Natural products OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
150000001457 metallic cations Chemical class 0.000 description 2
230000001537 neural effect Effects 0.000 description 2
150000002828 nitro derivatives Chemical class 0.000 description 2
TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 2
JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
239000000126 substance Substances 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
229910052727 yttrium Inorganic materials 0.000 description 2
OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
QOLRLVPABLMMKI-XSLAGTTESA-N (2s,5s)-1-[2-[(2s,5s)-2,5-diethylphospholan-1-yl]ethyl]-2,5-diethylphospholane Chemical compound CC[C@H]1CC[C@H](CC)P1CCP1[C@@H](CC)CC[C@@H]1CC QOLRLVPABLMMKI-XSLAGTTESA-N 0.000 description 1
IRCDUOCGSIGEAI-XUXIUFHCSA-N (2s,5s)-1-[2-[(2s,5s)-2,5-dimethylphospholan-1-yl]ethyl]-2,5-dimethylphospholane Chemical compound C[C@H]1CC[C@H](C)P1CCP1[C@@H](C)CC[C@@H]1C IRCDUOCGSIGEAI-XUXIUFHCSA-N 0.000 description 1
PPIBJOQGAJBQDF-VXNVDRBHSA-N (4r,5s)-4-methyl-5-phenyl-1,3-oxazolidin-2-one Chemical compound C[C@H]1NC(=O)O[C@H]1C1=CC=CC=C1 PPIBJOQGAJBQDF-VXNVDRBHSA-N 0.000 description 1
239000001602 (E)-hex-3-enoic acid Substances 0.000 description 1
JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
RHDYQUZYHZWTCI-UHFFFAOYSA-N 1-methoxy-4-phenylbenzene Chemical group C1=CC(OC)=CC=C1C1=CC=CC=C1 RHDYQUZYHZWTCI-UHFFFAOYSA-N 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
AYXYPKUFHZROOJ-UHFFFAOYSA-N 3-(azaniumylmethyl)-5-methylhexanoate Chemical compound CC(C)CC(CN)CC(O)=O AYXYPKUFHZROOJ-UHFFFAOYSA-N 0.000 description 1
HZHBIPCFTRPWKY-UHFFFAOYSA-M 3-cyano-5-methylhex-3-enoate Chemical compound CC(C)C=C(C#N)CC([O-])=O HZHBIPCFTRPWKY-UHFFFAOYSA-M 0.000 description 1
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
PKNTXEJOWDTDLN-UHFFFAOYSA-N 4-methyl-2-methylidenepentanenitrile Chemical compound CC(C)CC(=C)C#N PKNTXEJOWDTDLN-UHFFFAOYSA-N 0.000 description 1
206010003591 Ataxia Diseases 0.000 description 1
238000005712 Baylis-Hillman reaction Methods 0.000 description 1
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
108090000489 Carboxy-Lyases Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
XXHDAWYDNSXJQM-UHFFFAOYSA-N Chloride-3-Hexenoic acid Natural products CCC=CCC(O)=O XXHDAWYDNSXJQM-UHFFFAOYSA-N 0.000 description 1
241000490229 Eucephalus Species 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
238000010268 HPLC based assay Methods 0.000 description 1
238000006105 Hofmann reaction Methods 0.000 description 1
AMIMRNSIRUDHCM-UHFFFAOYSA-N Isopropylaldehyde Chemical compound CC(C)C=O AMIMRNSIRUDHCM-UHFFFAOYSA-N 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
206010061296 Motor dysfunction Diseases 0.000 description 1
241000906683 Nantis Species 0.000 description 1
JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
150000003973 alkyl amines Chemical class 0.000 description 1
125000005910 alkyl carbonate group Chemical group 0.000 description 1
MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
230000000573 anti-seizure effect Effects 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
229960003965 antiepileptics Drugs 0.000 description 1
239000011260 aqueous acid Substances 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
235000010290 biphenyl Nutrition 0.000 description 1
239000004305 biphenyl Substances 0.000 description 1
230000003925 brain function Effects 0.000 description 1
239000012267 brine Substances 0.000 description 1
244000309464 bull Species 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
125000002837 carbocyclic group Chemical group 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
OEERIBPGRSLGEK-UHFFFAOYSA-N carbon dioxide;methanol Chemical compound OC.O=C=O OEERIBPGRSLGEK-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
230000006315 carbonylation Effects 0.000 description 1
238000005810 carbonylation reaction Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000012230 colorless oil Substances 0.000 description 1
238000012777 commercial manufacturing Methods 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
230000036461 convulsion Effects 0.000 description 1
230000002920 convulsive effect Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
YPJHNVOLWRBDQA-UHFFFAOYSA-N cyano hex-2-enoate Chemical compound CCCC=CC(=O)OC#N YPJHNVOLWRBDQA-UHFFFAOYSA-N 0.000 description 1
AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 1
SGDINNZGYDHHKM-UHFFFAOYSA-N dilithium;trimethylsilylazanide Chemical compound [Li+].[Li+].C[Si](C)(C)[NH-].C[Si](C)(C)[NH-] SGDINNZGYDHHKM-UHFFFAOYSA-N 0.000 description 1
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
QKZWXPLBVCKXNQ-ROJLCIKYSA-N dipamp Chemical compound COC1=CC=CC=C1[P@@](C=1C=CC=CC=1)CC[P@@](C=1C(=CC=CC=1)OC)C1=CC=CC=C1 QKZWXPLBVCKXNQ-ROJLCIKYSA-N 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
WBQBMWWPFBMMOD-SECBINFHSA-N ethyl (3r)-3-cyano-5-methylhexanoate Chemical compound CCOC(=O)C[C@H](C#N)CC(C)C WBQBMWWPFBMMOD-SECBINFHSA-N 0.000 description 1
238000000605 extraction Methods 0.000 description 1
230000001815 facial effect Effects 0.000 description 1
238000011049 filling Methods 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
229960002989 glutamic acid Drugs 0.000 description 1
JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
125000001475 halogen functional group Chemical group 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
231100001261 hazardous Toxicity 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
XXHDAWYDNSXJQM-UHFFFAOYSA-M hex-3-enoate Chemical compound CCC=CCC([O-])=O XXHDAWYDNSXJQM-UHFFFAOYSA-M 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
LVHBHZANLOWSRM-UHFFFAOYSA-N itaconic acid Chemical class OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
MMSQMDXHUFANGO-UHFFFAOYSA-N methyl 3-cyano-5-methylhex-3-enoate Chemical compound COC(=O)CC(C#N)=CC(C)C MMSQMDXHUFANGO-UHFFFAOYSA-N 0.000 description 1
BQCGQKLXPMPVDP-UHFFFAOYSA-N methyl 3-cyano-5-methylhexanoate Chemical compound COC(=O)CC(C#N)CC(C)C BQCGQKLXPMPVDP-UHFFFAOYSA-N 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
238000010979 pH adjustment Methods 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
125000005561 phenanthryl group Chemical group 0.000 description 1
229910000073 phosphorus hydride Inorganic materials 0.000 description 1
229940094035 potassium bromide Drugs 0.000 description 1
XYLSFBDMLBNBMI-UHFFFAOYSA-M potassium;3-cyano-5-methylhex-3-enoate Chemical compound [K+].CC(C)C=C(C#N)CC([O-])=O XYLSFBDMLBNBMI-UHFFFAOYSA-M 0.000 description 1
AYXYPKUFHZROOJ-SSDOTTSWSA-N pregabalin Chemical compound CC(C)C[C@@H](CN)CC(O)=O AYXYPKUFHZROOJ-SSDOTTSWSA-N 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000012545 processing Methods 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000003586 protic polar solvent Substances 0.000 description 1
238000010926 purge Methods 0.000 description 1
239000012066 reaction slurry Substances 0.000 description 1
229910052703 rhodium Inorganic materials 0.000 description 1
MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
125000003107 substituted aryl group Chemical group 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
SCNWCHWHTLUICV-UHFFFAOYSA-N tert-butylazanium;3-cyano-5-methylhex-3-enoate Chemical compound CC(C)(C)[NH3+].CC(C)C=C(C#N)CC([O-])=O SCNWCHWHTLUICV-UHFFFAOYSA-N 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
XXHDAWYDNSXJQM-ONEGZZNKSA-N trans-hex-3-enoic acid Chemical compound CC\C=C\CC(O)=O XXHDAWYDNSXJQM-ONEGZZNKSA-N 0.000 description 1
238000012546 transfer Methods 0.000 description 1
IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/23—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same unsaturated acyclic carbon skeleton
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C253/00—Preparation of carboxylic acid nitriles
- C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/19—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same saturated acyclic carbon skeleton

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Psychiatry (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Catalysts (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

OA1200200227A 2000-01-27 2001-01-11 Asymmetric synthesis of pregabalin. OA12167A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US17835900P	2000-01-27	2000-01-27
US19042700P	2000-03-17	2000-03-17

Publications (1)

Publication Number	Publication Date
OA12167A true OA12167A (en)	2006-05-08

Family

ID=26874236

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200200227A OA12167A (en)	2000-01-27	2001-01-11	Asymmetric synthesis of pregabalin.

Country Status (50)

Country	Link
US (1)	US6891059B2 (fr)
EP (1)	EP1250311B1 (fr)
JP (2)	JP4235384B2 (fr)
KR (1)	KR100549748B1 (fr)
CN (1)	CN1210253C (fr)
AP (1)	AP1438A (fr)
AR (1)	AR028499A1 (fr)
AT (1)	ATE261930T1 (fr)
AU (1)	AU777046B2 (fr)
BG (1)	BG65560B1 (fr)
BR (1)	BRPI0107863B8 (fr)
CA (1)	CA2396090C (fr)
CO (1)	CO5251411A1 (fr)
CR (1)	CR6703A (fr)
CU (1)	CU23221A3 (fr)
CY (1)	CY2004011I1 (fr)
CZ (1)	CZ302838B6 (fr)
DE (1)	DE60102356T2 (fr)
DK (1)	DK1250311T3 (fr)
DZ (1)	DZ3268A1 (fr)
EA (1)	EA004934B1 (fr)
EE (1)	EE05216B1 (fr)
EG (1)	EG24138A (fr)
ES (1)	ES2219493T3 (fr)
GE (1)	GEP20043236B (fr)
HN (1)	HN2001000010A (fr)
HR (1)	HRP20020627B1 (fr)
HU (1)	HU228815B1 (fr)
IL (2)	IL150633A0 (fr)
IS (1)	IS2038B (fr)
MA (1)	MA26869A1 (fr)
ME (1)	ME00921B (fr)
MX (1)	MXPA02007307A (fr)
MY (1)	MY127152A (fr)
NO (1)	NO327958B1 (fr)
NZ (1)	NZ519551A (fr)
OA (1)	OA12167A (fr)
PA (1)	PA8510501A1 (fr)
PE (1)	PE20011063A1 (fr)
PL (1)	PL203985B1 (fr)
PT (1)	PT1250311E (fr)
RS (1)	RS50257B (fr)
SI (1)	SI1250311T1 (fr)
SK (1)	SK287303B6 (fr)
SV (1)	SV2002000295A (fr)
TN (1)	TNSN01016A1 (fr)
TR (1)	TR200400953T4 (fr)
TW (1)	TWI288128B (fr)
UA (1)	UA75584C2 (fr)
WO (1)	WO2001055090A1 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0934061B3 (fr)	1996-07-24	2015-01-21	Warner-Lambert Company LLC	Isobutylgaba et ses derives utilises pour le traitement de la douleur
TR200400953T4 (tr) *	2000-01-27	2004-07-21	Warner Lambert Company	Pregabalinin asimetrik sentezi.
US6687187B2 (en) *	2000-08-11	2004-02-03	Phonak Ag	Method for directional location and locating system
EP1543831A1 (fr) *	2003-12-18	2005-06-22	Pfizer GmbH Arzneimittelwerk Gödecke	Composition de pregabaline
PT1727620E (pt) *	2004-03-12	2007-11-05	Warner Lambert Co	Ligandos de biofosfina c1-simétricos e a sua utilização na síntese assimétrica da pregabalina
UA82292C2 (uk) *	2004-04-14	2008-03-25	Пфайзер Продактс Инк.	Спосіб стереоселективного біоперетворення аліфатичних динітрилів в ціанокарбонові кислоти (варіанти)
CN1972904B (zh) *	2004-06-21	2011-02-02	沃尼尔·朗伯有限责任公司	普瑞巴林和相关化合物的制备
CN101160281A (zh) *	2005-04-06	2008-04-09	特瓦制药工业有限公司	结晶形态的普瑞巴林
US7488846B2 (en) *	2005-04-11	2009-02-10	Teva Pharmaceuical Industries Ltd.	Pregabalin free of lactam and a process for preparation thereof
MX2007012606A (es) *	2005-04-11	2008-01-11	Teva Pharma	Proceso para elaborar (s)-pregabalina.
MX2007000525A (es) *	2005-05-10	2007-03-28	Teva Pharma	Pregabalina libre de acido isobutilglutarico y un proceso para la preparacion de ella.
WO2006122258A1 (fr)	2005-05-10	2006-11-16	Teva Pharmaceutical Industries Ltd.	Procede pour preparer de la pregabaline et des sels de celle-ci
ES2372700T3 (es)	2005-05-10	2012-01-25	Teva Pharmaceutical Industries Ltd	Resolución óptica del ácido 3-carbamoilmetil-5-metil hexanoico.
US20060270871A1 (en) *	2005-05-30	2006-11-30	Khanduri Chandra H	Polymorphic form i of pregabalin and processes for its preparation
CN100410242C (zh) *	2005-06-23	2008-08-13	江苏恩华药业股份有限公司	普瑞巴林中间体及其制备方法
WO2007035789A1 (fr)	2005-09-19	2007-03-29	Teva Pharmaceutical Industries Ltd.	Acides 3-carbamoylméthyl-5-méthylhexanoïques chiraux, intermédiaires clés pour la nouvelle synthèse de la (s)-prégabaline
NL2000281C2 (nl) *	2005-11-02	2007-08-07	Pfizer Prod Inc	Vaste farmaceutische samenstellingen die pregabaline bevatten.
WO2007127309A2 (fr) *	2006-04-24	2007-11-08	Teva Pharmaceutical Industries Ltd.	Procede de synthese d'acide 3-isobutylglutarique
WO2007139933A2 (fr)	2006-05-24	2007-12-06	Teva Pharmaceutical Industries Ltd.	Procédés pour la préparation d'acide r-(+)-3-(carbamoyl méthyl)-5-méthylhexanoïque et de sels de celui-ci
WO2007143113A2 (fr) *	2006-05-31	2007-12-13	Teva Pharmaceutical Industries Ltd.	Utilisation de la résolution enzymatique pour la préparation d'intermédiaires de prégabaline
WO2007143152A2 (fr) *	2006-05-31	2007-12-13	Teva Pharmaceutical Industries Ltd.	Préparation de (s)-prégabaline nitrile
EP1903027A1 (fr) *	2006-09-13	2008-03-26	Novartis AG	Procédé de préparation de l' acide amino-4 butyrique ou de ses derivés et leur utilisation pour la préparation des inhibiteurs NEP
TW200846308A (en)	2007-03-22	2008-12-01	Teva Pharma	Synthesis of (s)-(+)-3-(aminomethyl)-5-methyl hexanoic acid
US8168828B2 (en)	2007-06-25	2012-05-01	Msn Laboratories, Limited	Process for the preparation of pregabalin
KR100846419B1 (ko) *	2007-08-10	2008-07-15	한국과학기술원	프레가발린의 신규한 제조 방법
WO2009046309A2 (fr) *	2007-10-03	2009-04-09	Teva Pharmaceutical Industries Ltd.	Prégabaline-4-éliminée, prégabaline-5-éliminée, leur utilisation en tant que marqueur de référence et standard et procédé de production de prégabaline contenant de faibles taux de ceux-ci
EP2053040A1 (fr) *	2007-10-26	2009-04-29	Chemo Ibérica, S.A.	Intermédiaires de la Prégabaline et leurs procédés de préparation et Prégabaline
EP2225199A2 (fr) *	2007-12-18	2010-09-08	Watson Pharma Private Limited	Procédé perfectionné pour la préparation de (s)-prégabaline
EP2222630A1 (fr) *	2007-12-26	2010-09-01	Generics (UK) Limited	Procédés de préparation de la prégabaline
AU2008345851B2 (en) *	2008-01-10	2012-08-16	Sumitomo Chemical Company, Limited	Method for producing cyclopropane carboxylic acid compound and intermediate therefor
EP2110372A1 (fr)	2008-04-16	2009-10-21	Chemo Ibérica, S.A.	Intermédiaires pour la préparation de prégabaline et leur procédé de préparation
SG157299A1 (en)	2008-05-09	2009-12-29	Agency Science Tech & Res	Diagnosis and treatment of kawasaki disease
SI2294207T1 (sl)	2008-05-21	2013-01-31	Sandoz Ag	Postopek za stereoselektivno encimatsko hidrolizo estra 5-metil-3-nitrometil-heksanojske kisline
WO2009158343A1 (fr) *	2008-06-23	2009-12-30	Teva Pharmaceutical Industries, Ltd.	Synthèse enzymatique stéréosélective de l’ester (s) ou (r)-isobutylglutarique
WO2010070593A2 (fr)	2008-12-19	2010-06-24	Pfizer Ireland Pharmaceuticals	Esters de malonate
CN101987826A (zh) *	2009-08-04	2011-03-23	铜陵凯顺生物科技有限公司	一种(3s)-3-氨甲基-5-甲基己酸的合成方法
WO2011141923A2 (fr)	2010-05-14	2011-11-17	Lupin Limited	Synthèse améliorée d'un ester alkylique optiquement pur de l'acide (s) - 3-cyano-5-méthyl-hexanoïque, intermédiaire de la (s)-prégabaline
US8212072B2 (en)	2010-08-13	2012-07-03	Divi's Laboratories, Ltd.	Process for the preparation of pregabalin
WO2012025861A1 (fr) *	2010-08-23	2012-03-01	Pfizer Manufacturing Ireland	Procédé de préparation de dérivés d'acide (s)-3-cyano-5-méthylhexanoïque et de prégabaline
CN102464594B (zh) *	2010-11-17	2014-06-25	凯瑞斯德生化(苏州)有限公司	普瑞巴林的中间体化合物的制备方法
US9422230B2 (en)	2013-05-09	2016-08-23	Council Of Scientific And Industrial Research	Process for the preparation of an anticonvulsant agent pregabalin hydrochloride
WO2016075082A1 (fr)	2014-11-10	2016-05-19	Sandoz Ag	Amination réductrice stéréosélective d'aldéhydes alpha-chiraux au moyen d'ω-transaminases pour la synthèse de précurseurs de la prégabaline et du brivaracétam
WO2017019791A1 (fr)	2015-07-27	2017-02-02	Teva Pharmaceuticals International Gmbh	Synthèse de (s)-prégabaline

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS588390B2 (ja) *	1978-05-23	1983-02-15	住友化学工業株式会社	光学活性ω↓−シアノ↓−α↓−アシルアミノ酸誘導体の製造法
US4939288A (en) *	1989-01-23	1990-07-03	Monsanto Company	Method of preparing (R)-succinic acid derivatives
US6197819B1 (en) *	1990-11-27	2001-03-06	Northwestern University	Gamma amino butyric acid analogs and optical isomers
US5171892A (en) *	1991-07-02	1992-12-15	E. I. Du Pont De Nemours And Company	Chiral phospholanes via chiral 1,4-diol cyclic sulfates
US5616793A (en) *	1995-06-02	1997-04-01	Warner-Lambert Company	Methods of making (S)-3-(aminomethyl)-5-methylhexanoic acid
US5637767A (en) *	1995-06-07	1997-06-10	Warner-Lambert Company	Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid
US5840965A (en) *	1996-06-24	1998-11-24	E. I. Du Pont De Nemours And Company	Process for the production of purified telephthalic acid
EP0934061B3 (fr) *	1996-07-24	2015-01-21	Warner-Lambert Company LLC	Isobutylgaba et ses derives utilises pour le traitement de la douleur
US6127418A (en) *	1997-08-20	2000-10-03	Warner-Lambert Company	GABA analogs to prevent and treat gastrointestinal damage
EP1042270B1 (fr)	1997-12-17	2003-04-09	Chirotech Technology Limited	Hydrogenation asymetrique
WO1999052852A1 (fr)	1998-04-09	1999-10-21	Chirotech Technology Limited	Hydrogenation asymetrique
TR200400953T4 (tr) *	2000-01-27	2004-07-21	Warner Lambert Company	Pregabalinin asimetrik sentezi.

2001
- 2001-01-11 TR TR2004/00953T patent/TR200400953T4/xx unknown
- 2001-01-11 EP EP01900035A patent/EP1250311B1/fr not_active Expired - Lifetime
- 2001-01-11 CN CNB018041701A patent/CN1210253C/zh not_active Expired - Fee Related
- 2001-01-11 ME MEP-2008-447A patent/ME00921B/me unknown
- 2001-01-11 HU HU0204307A patent/HU228815B1/hu not_active IP Right Cessation
- 2001-01-11 EE EEP200200403A patent/EE05216B1/xx not_active IP Right Cessation
- 2001-01-11 CA CA002396090A patent/CA2396090C/fr not_active Expired - Fee Related
- 2001-01-11 OA OA1200200227A patent/OA12167A/en unknown
- 2001-01-11 IL IL15063301A patent/IL150633A0/xx unknown
- 2001-01-11 DE DE60102356T patent/DE60102356T2/de not_active Expired - Lifetime
- 2001-01-11 PT PT01900035T patent/PT1250311E/pt unknown
- 2001-01-11 CZ CZ20022520A patent/CZ302838B6/cs not_active IP Right Cessation
- 2001-01-11 GE GEAP20016551A patent/GEP20043236B/en unknown
- 2001-01-11 NZ NZ519551A patent/NZ519551A/en not_active IP Right Cessation
- 2001-01-11 SI SI200130109T patent/SI1250311T1/xx unknown
- 2001-01-11 PL PL357077A patent/PL203985B1/pl unknown
- 2001-01-11 MX MXPA02007307A patent/MXPA02007307A/es active IP Right Grant
- 2001-01-11 AU AU22138/01A patent/AU777046B2/en not_active Ceased
- 2001-01-11 KR KR1020027009629A patent/KR100549748B1/ko not_active Expired - Fee Related
- 2001-01-11 HR HR20020627A patent/HRP20020627B1/xx not_active IP Right Cessation
- 2001-01-11 EA EA200200642A patent/EA004934B1/ru not_active IP Right Cessation
- 2001-01-11 ES ES01900035T patent/ES2219493T3/es not_active Expired - Lifetime
- 2001-01-11 US US10/182,656 patent/US6891059B2/en not_active Expired - Lifetime
- 2001-01-11 AT AT01900035T patent/ATE261930T1/de active
- 2001-01-11 AP APAP/P/2002/002588A patent/AP1438A/en active
- 2001-01-11 DZ DZ013268A patent/DZ3268A1/fr active
- 2001-01-11 WO PCT/IB2001/000024 patent/WO2001055090A1/fr not_active Ceased
- 2001-01-11 SK SK1078-2002A patent/SK287303B6/sk not_active IP Right Cessation
- 2001-01-11 BR BRPI0107863A patent/BRPI0107863B8/pt not_active IP Right Cessation
- 2001-01-11 RS YU56202A patent/RS50257B/sr unknown
- 2001-01-11 JP JP2001555033A patent/JP4235384B2/ja not_active Expired - Fee Related
- 2001-01-11 DK DK01900035T patent/DK1250311T3/da active
- 2001-01-19 TW TW090101221A patent/TWI288128B/zh not_active IP Right Cessation
- 2001-01-23 MY MYPI20010329A patent/MY127152A/en unknown
- 2001-01-23 PA PA20018510501A patent/PA8510501A1/es unknown
- 2001-01-24 HN HN2001000010A patent/HN2001000010A/es unknown
- 2001-01-24 EG EG20010073A patent/EG24138A/xx active
- 2001-01-24 PE PE2001000078A patent/PE20011063A1/es not_active Application Discontinuation
- 2001-01-24 CO CO01005266A patent/CO5251411A1/es active IP Right Grant
- 2001-01-25 AR ARP010100316A patent/AR028499A1/es not_active Application Discontinuation
- 2001-01-26 SV SV2001000295A patent/SV2002000295A/es active IP Right Grant
- 2001-01-26 TN TNTNSN01016A patent/TNSN01016A1/fr unknown
- 2001-11-01 UA UA2002065143A patent/UA75584C2/uk unknown
2002
- 2002-06-19 IS IS6430A patent/IS2038B/is unknown
- 2002-06-19 CU CU20020122A patent/CU23221A3/es unknown
- 2002-06-20 BG BG106849A patent/BG65560B1/bg unknown
- 2002-07-08 IL IL150633A patent/IL150633A/en not_active IP Right Cessation
- 2002-07-16 CR CR6703A patent/CR6703A/es unknown
- 2002-07-23 MA MA26738A patent/MA26869A1/fr unknown
- 2002-07-26 NO NO20023582A patent/NO327958B1/no not_active IP Right Cessation
2004
- 2004-12-20 CY CY2004011C patent/CY2004011I1/el unknown
2008
- 2008-09-30 JP JP2008254068A patent/JP4886753B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
NO20023582D0 (no)	2002-07-26
BR0107863A (pt)	2002-11-05
IL150633A (en)	2009-08-03
NO20023582L (no)	2002-09-02
JP4886753B2 (ja)	2012-02-29
SK287303B6 (sk)	2010-06-07
CR6703A (es)	2003-06-24
CZ20022520A3 (cs)	2002-10-16
HU228815B1 (en)	2013-05-28
HRP20020627B1 (hr)	2011-01-31
EE200200403A (et)	2003-10-15
CZ302838B6 (cs)	2011-12-07
HUP0204307A2 (hu)	2003-06-28
YU56202A (sh)	2006-01-16
BR0107863B1 (pt)	2013-06-18
IS6430A (is)	2002-06-19
ES2219493T3 (es)	2004-12-01
CU23221A3 (es)	2007-07-20
AP2002002588A0 (en)	2002-09-30
EG24138A (en)	2008-08-06
US6891059B2 (en)	2005-05-10
CY2004011I1 (el)	2010-07-28
EA200200642A1 (ru)	2002-12-26
SV2002000295A (es)	2002-06-07
TWI288128B (en)	2007-10-11
AR028499A1 (es)	2003-05-14
DE60102356D1 (de)	2004-04-22
WO2001055090A1 (fr)	2001-08-02
RS50257B (sr)	2009-07-15
CO5251411A1 (es)	2003-02-28
MA26869A1 (fr)	2004-12-20
NZ519551A (en)	2004-02-27
US20030212290A1 (en)	2003-11-13
JP2003520841A (ja)	2003-07-08
MY127152A (en)	2006-11-30
SK10782002A3 (sk)	2002-11-06
PA8510501A1 (es)	2002-02-21
PE20011063A1 (es)	2001-10-18
JP4235384B2 (ja)	2009-03-11
TNSN01016A1 (fr)	2005-11-10
EP1250311B1 (fr)	2004-03-17
IL150633A0 (en)	2003-02-12
CN1396905A (zh)	2003-02-12
KR100549748B1 (ko)	2006-02-08
BG106849A (en)	2003-03-31
HN2001000010A (es)	2001-06-13
AP1438A (en)	2005-05-23
CA2396090A1 (fr)	2001-08-02
PT1250311E (pt)	2004-07-30
EA004934B1 (ru)	2004-10-28
EE05216B1 (et)	2009-10-15
SI1250311T1 (en)	2004-10-31
UA75584C2 (uk)	2006-05-15
TR200400953T4 (tr)	2004-07-21
HUP0204307A3 (en)	2003-07-28
IS2038B (is)	2005-08-15
ME00921B (me)	2012-06-20
KR20020073187A (ko)	2002-09-19
MXPA02007307A (es)	2002-11-29
DZ3268A1 (fr)	2001-08-02
NO327958B1 (no)	2009-10-26
JP2009073841A (ja)	2009-04-09
CA2396090C (fr)	2006-01-10
AU777046B2 (en)	2004-09-30
AU2213801A (en)	2001-08-07
DK1250311T3 (da)	2004-08-16
HRP20020627A2 (en)	2004-08-31
BG65560B1 (bg)	2008-12-30
CN1210253C (zh)	2005-07-13
DE60102356T2 (de)	2005-02-17
EP1250311A1 (fr)	2002-10-23
PL357077A1 (en)	2004-07-12
ATE261930T1 (de)	2004-04-15
PL203985B1 (pl)	2009-11-30
BRPI0107863B8 (pt)	2017-04-25
GEP20043236B (en)	2004-05-25

Publication	Publication Date	Title
EP1250311B1 (fr)	2004-03-17	Synthese asymetrique de pregabaline
SK283507B6 (sk)	2003-08-05	Spôsob prípravy kyseliny (±)-3-(aminometyl)-5-metylhexánovej
JPH0987258A (ja)	1997-03-31	オキサゾリン類、その製造方法およびそれを用いる不斉シクロプロパンカルボン酸類の製造方法
KR100846419B1 (ko)	2008-07-15	프레가발린의 신규한 제조 방법
CN1329368C (zh)	2007-08-01	制备富含对映体的化合物的方法
GB2422603A (en)	2006-08-02	Preparation of 2-substituted-propionic acids and amides by enantioselective hydrogenation
PL210934B1 (pl)	2012-03-30	Optycznie czynne pochodne bisoksazoliny, sposób wytwarzania tych związków, substraty i sposób ich wytwarzania
CN114456089B (zh)	2023-05-23	一种路易斯酸促进的烯烃和肟酯与胺的三组分反应方法
ZA200205878B (en)	2003-07-23	Asymmetric synthesis of pregabalin.
JP2025134168A (ja)	2025-09-17	銅触媒による立体特異的シアノ化反応
JPH0415776B2 (fr)	1992-03-19
HK1051679B (en)	2005-10-28	Asymmetric synthesis of pregabalin
HK1051679A1 (en)	2003-08-15	Asymmetric synthesis of pregabalin
JPH03506036A (ja)	1991-12-26	アルカンとホルメートとの反応によるカルボン酸の製造方法